
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
NEW YORK - Metastatic melanoma of the brain has a terrible prognosis, with a median survival of three to four months.






